

NTRK Gene Fusion - Positive Advanced or Recurrent Solid Tumors, a Rare Cancer Caused by Specific Changes in the Genes

NCT04945330

Status RECRUITING
Sponsor Bayer
Enrollment 100 participants

Key Eligibility Criteria

Inclusion (1)

- Patients who are treated with larotrectinib or decided to be treated with larotrectinib, under routine clinical practice.

Exclusion (1)

- Participation in an investigational program with interventions outside of routine clinical practice

Locations (1 total)

Many locations, Multiple Locations, Japan